Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$150.33-1.32%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · MRK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks MRK against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing regulatory approvals, clinical milestones, and new indications for KEYTRUDA and other oncology candidates.
Stated as a priority in 7 of last 7 quarters. KEYTRUDA/KEYTRUDA QLEX sales grew from $7.2B in 2025-Q1 to $8.4B in 2026-Q2 (+17% nominal over 6 quarters). Management consistently highlighted multiple FDA approvals and positive Phase 3 results across oncology. The trajectory is delivering with sustained sales growth and pipeline progress.
“Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX”
“Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline”
“Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE”
“Continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches”
“Continued to advance its broad and diverse pipeline with multiple regulatory and clinical milestones in oncology”
“Continued to advance its broad and diverse pipeline, achieving key regulatory and clinical milestones across a range of therapeutic areas including oncology”
“Augmented Diverse Pipeline Through Exclusive Global Licenses and Presented Positive Topline Results From Pivotal Phase 3 Trial of Subcutaneous Pembrolizumab”
Management has repeatedly raised and narrowed full-year 2026 revenue guidance reflecting confidence in sales growth.
Stated as a priority in 5 of last 5 quarters. Management raised and narrowed full-year revenue guidance from $65.5-$67.0B in early 2026 to $66.3-$67.3B by mid-2026. This reflects confidence in sales growth, consistent with reported quarterly revenues rising from $15.8B in 2025-Q2 to $16.6B in 2026-Q2. The trajectory is delivering.
“The Company is raising and narrowing the range for its full-year sales outlook and now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion”
Management has raised and narrowed full-year 2026 non-GAAP EPS guidance despite recent GAAP losses due to acquisition charges.
Stated as a priority in 5 of last 5 quarters. Management narrowed and raised non-GAAP EPS guidance to $5.04-$5.16 in early 2026 but lowered it to $2.66-$2.76 by mid-2026, reflecting acquisition charges. Despite GAAP losses in 2026-Q1 and Q2, non-GAAP EPS guidance reflects adjusted expectations. The trajectory shows mixed delivery due to charges.
“The Company now expects full-year 2026 non-GAAP EPS to be between $2.66 and $2.76”
Focus on expanding sales in both Livestock and Companion Animal portfolios with new product launches and higher demand.
Stated as a priority in 6 of last 6 quarters. Animal Health sales increased from $1.646B in 2025-Q2 to $1.775B in 2026-Q2 (+8%). Growth was driven by both Livestock and Companion Animal portfolios with new product launches and higher demand. The trajectory is delivering consistent growth.
Implement cost savings program to redirect resources to growth drivers, aiming for $3 billion annual savings by end of 2027.
Newly stated in 2025-Q2 and reiterated in 2025-Q1. Management announced a multiyear optimization initiative targeting $3 billion in annual cost savings by end of 2027 to reinvest in growth areas. Financials show some expense fluctuations but no direct quantification of savings yet; trajectory is early stage.
“Announced Multiyear Optimization Initiative Anticipated To Result in Approximately $3.0 Billion of Annual Cost Savings by the End of 2027”
Over the trailing year it converted 2.23x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Now Expects Sales To Be Between $65.8 Billion and $67.0 Billion”
“Now Expects full-year 2025 sales to be between $64.3 billion and $65.3 billion”
“Now Expects Worldwide Sales To Be Between $64.5 Billion and $65.0 Billion”
“Narrows Expected Worldwide Sales Range To Be Between $64.3 Billion and $65.3 Billion”
“Narrows and Raises Expected Non-GAAP EPS Range To Be Between $5.04 and $5.16”
“Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93 and $8.98”
“Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93 and $8.98”
“Narrows Expected Non-GAAP EPS Range To Be Between $8.87 and $8.97”
“Animal Health Sales Were $1.8 Billion (8% Growth; 5% Growth ex-FX)”
“Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)”
“Animal Health Sales Were $1.6 Billion, Growth of 11%”
“Animal Health Sales Grew 9% to $1.6 Billion”
“Animal Health Sales Were $1.6 Billion, Growth of 11%”
“Animal Health Sales Grew 5% to $1.6 Billion”
“Announced Multiyear Optimization Initiative Anticipated To Result in Approximately $3.0 Billion of Annual Cost Savings by the End of 2027”